tbuckley/cabot-search huggingface dataset:
Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species
Authors: Kai Chen, Pengcheng Qiu, Yu Yuan, Lin Zheng, Jianbo He, Chao Wang, Qiang Guo, Jacob Kenny, Qian Liu, Jinmin Zhao, Junhao Chen, Jennifer Tickner, Shunwu Fan, Xianfeng Lin, Jiake Xu
Journal: Theranostics (2019)

Rationale: Growing evidence indicates that intracellular reactive oxygen species (ROS) accumulation is a critical factor in the development of osteoporosis by triggering osteoclast formation and function.Pseurotin A (Pse) is a secondary metabolite isolated from Aspergillus fumigatus with antioxidant properties, recently shown to exhibit with a wide range of potential therapeutic applications.However, its effects on osteoporosis remain unknown.This study aimed to explore whether Pse, by suppressing ROS levels, is able to inhibit osteoclastogenesis and prevent the bone loss induced by estrogen-deficiency in ovariectomized (OVX) mice. Methods:The effects of Pse on receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclastogenesis and bone resorptive function were examined by tartrate resistant acid phosphatase (TRAcP) staining and hydroxyapatite resorption assay.2',7'dichlorodihydrofluorescein diacetate (H2DCFDA) was used to detect intracellular ROS production in vitro.Western blot assay was used to identify proteins associated with ROS generation and scavenging as well as ROS-mediated signaling cascades including mitogenactivated protein kinases (MAPKs), NF-κB pathways, and nuclear factor of activated T cells 1 (NFATc1) activation.The expression of osteoclast-specific genes was assessed by qPCR.The in vivo potential of Pse was determined using an OVX mouse model administered with Pse or vehicle for 6 weeks.In vivo ROS production was assessed by intravenous injection of dihydroethidium (DHE) into OVX mice 24h prior to killing.After sacrifice, the bone samples were analyzed using μCT and histomorphometry to determine bone volume, osteoclast activity, and ROS level in vivo.Results: Pse was demonstrated to inhibit osteoclastogenesis and bone resorptive function in vitro, as well as the downregulation of osteoclast-specific genes including Acp5 (encoding TRAcP), Ctsk (encoding cathepsin K), and Mmp9 (encoding matrix metalloproteinase 9).Mechanistically, Pse suppressed intracellular ROS level by inhibiting RANKL-induced ROS production and enhancing ROS scavenging enzymes, subsequently suppressing MAPK pathway activation (ERK, P38, and JNK) and NF-κB pathways, as well as inhibiting NFATc1 signaling.μCT and histological results indicated that OVX resulted in significant bone loss, with dramatically increased numbers of osteoclasts on the bone surface as well as increased ROS levels in the bone marrow microenvironment; whereas Pse supplementation was capable of effectively preventing these OVX-induced changes. Conclusion:Pse was demonstrated for the first time as a novel alternative therapy for osteoclastrelated bone disease such as osteoporosis through suppressing ROS levels.
China Kidney Disease Network (CK-NET) 2015 Annual Data Report
Authors: Luxia Zhang, Ming-Hui Zhao, Li Zuo, Yue Wang, Feng Yu, Hong Zhang, Haibo Wang, Kunhao Bai, Rui Chen, Hong Chu, Lanxia Gan, Bixia Gao, Xiangxiang He, Lili Liu, Jianyan Long, Ying Shi, Zaiming Su, Xiaoyu Sun, Wen Tang, Fang Wang, Haibo Wang, Jinwei Wang, Song Wang, Yue Wang, Chao Yang, Feng Yu, Dongliang Zhang, Hong Zhang, Luxia Zhang, Minghui Zhao, Xinju Zhao, Liren Zheng, Zhiye Zhou, Li Zuo
Journal: Kidney International Supplements (2019)
Allergy to Rabbits
Authors: J. A. Price, J. L. Longbottom
Journal: Allergy (1986)

Investigations have been carried out into the presence of antibody light chains in rabbit allergenic extracts and the interference in RAST and crossed‐radioimmunoelectrophoresis (XRIE) caused by antibodies directed against them‐ A “non‐specific” uptake of radioactivity in XRIE has been demonstrated to be caused by direct cross‐linking of the 12 5 I rabbit anti‐human IgE by the sheep antibodies in the Immunoprecipitate of rabbit light chains. Preincubation with normal rabbit serum blocked this direct uptake of the labelled antibody and enabled specific IgE uptake on the light chains to be demonstrated for rabbit allergic sera. Verification of the allergenicity of the light chains was obtained from a specific light chain RAST. Elution from a Sephacryl S‐200 gel filtration column indicated a MW of approx. 50 Kd and confirmation of the component as light chain dimers, not Fab fragments, was obtained by allotyping for loci present on heavy chains and light chains in the Fab region. Light chains were detected in urine from rabbits of all ages and in extract of dust collected in a rabbit housing area. No background staining was observed in XRIE using rabbit antisera, either with rabbit allergic sera with specific IgE or with a human serum containing specific IgG antibodies to rabbit IgG. This latter serum also showed no evidence of uptake on all immunoprecipitates in systems using rabbit antisera, and did not give false positive RAST results when the labelled rabbit anti‐human IgE contained unlabelled rabbit IgG. Those sera with specific IgE to light chains showed no uptake in XRIE using rabbit antisera, indicating that the IgE was possibly specific for epitopes revealed by the dissociation of the whole IgG molecule.
SP0074 MRI in Psoriatic Arthritis - From Spine to Toes
Authors: K. G. Hermann
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Psoriatic arthritis (PsA) is one of the most exciting joint diseases. The clinical appearance of PsA is very diverse, involving the spine, sacroiliac joints, peripheral joints and entheses. Consequently, also imaging findings vary and in many cases only the combined interpretation of X-rays, ultrasound, CT and MRI will lead to the correct diagnosis. Research teams have tried to use MRI for further differentiation from rheumatoid arthritis or hand osteoarthritis, e.g. with the help of dynamic contrast-enhanced MRI, pattern recognition or single-joint high-resolution MRI. Those studies so far did not reveal distinct features for PsA to differentiate it from other inflammatory arthritides. The lecture will highlight typical findings in PsA on MRI from a clinical radiology perspective and will correlate these with X-ray findings and differential diagnoses as appropriate. The participants will learn how to use MRI in distinct situation in the diagnostic workup of patients with suspected PsA. Furthermore, new developments in quantifying disease activity will be presented. <h3>Disclosure of Interest</h3> K. G. Hermann Paid instructor for: Pfizer, MSD, AbbVie
Summary of Notifiable Infectious Diseases and Conditions — United States, 2015
Authors: Deborah A. Adams, Kimberly R. Thomas, Ruth Ann Jajosky, Loretta Foster, Gitangali Baroi, Pearl Sharp, Diana H. Onweh, Alan W. Schley, Willie J. Anderson
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The Summary of Notifiable Infectious Diseases and Conditions - United States, 2015 (hereafter referred to as the summary) contains the official statistics, in tabular and graphical form, for the reported occurrence of nationally notifiable infectious diseases and conditions in the United States for 2015. Unless otherwise noted, data are final totals for 2015 reported as of June 30, 2016. These statistics are collected and compiled from reports sent by U.S. state and territories, New York City, and District of Columbia health departments to the National Notifiable Diseases Surveillance System (NNDSS), which is operated by CDC in collaboration with the Council of State and Territorial Epidemiologists (CSTE). This summary is available at https://www.cdc.gov/MMWR/MMWR_nd/index.html. This site also includes summary publications from previous years.
CCR2+ Monocyte-Derived Ly6C-F4/80+ Fibrocytes Inhibit Collagen Degradation and Contribute to the Development of Colon Fibrosis Via Production of TIMP-1
Authors: Masahiro Masuya, Naoki Kuroda, Kensuke Hachiya, Isao Tawara, Yuki Kageyama, Kohshi Ohishi, Hiroshi Miwa, Naoyuki Katayama
Journal: Blood (2018)
AIDS-Related Kaposi Sarcoma, Version 2.2019
Authors: Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, Deborah A. Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2019)

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.
Quick Uptakes
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol‐Related Liver Disease
Authors: Nicole T. Shen, Annaheta Salajegheh, Robert S. Brown
Journal: Hepatology (2019)

Alcohol‐related liver disease (ALD) is highly prevalent and appears to be increasingly reported with worsening mortality; thus, optimizing care in this patient population is imperative. This will require a multidisciplinary, multifaceted approach that includes recognizing alcohol use disorder (AUD) and existing treatments for AUD. We must also acknowledge the full spectrum of ALD clinically and histologically. For example, our current clinical definitions of alcohol‐related hepatitis (AH) do not address that &gt;95% of severe AH occurs in the setting of cirrhosis with &lt;60% of liver explants having hepatitis. Given that the majority of ALD studies rely on clinical diagnosis and lack pathologic confirmation, prior data on the efficacy of medical treatment or use of transplantation are likely limited by intertrial and intratrial heterogeneity. Added limitations of the current field include the inconsistent reporting of relapse with the use of varying definitions and unreliable assessments. Moreover, studies fail to consistently capture the data variables that likely influence the main outcomes of interest in this population—mortality and relapse—and a global effort to create a standardized data collection tool moving forward could help effectively and efficiently aid in the advancement of this field. Conclusion: To optimize patient care and make best use of a limited resource, a systematic change in the approach to research in this population must be undertaken that creates consistent definitions for use in future research to generate reliable and reproducible results. With this in mind, we concisely reviewed the literature to summarize the current state of treating and managing ALD, the heterogeneity in definitions, and the significant opportunities for clinical and research improvement.
Internet-Based Cognitive-Behavioural Intervention for Women with Premenstrual Dysphoric Disorder: A Randomized Controlled Trial
Authors: Cornelia Weise, Gudrun Kaiser, Carolyn Janda, Johanna N. Kues, Gerhard Andersson, Jana Strahler, Maria Kleinstäuber
Journal: Psychotherapy and Psychosomatics (2019)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Given the high prevalence of clinically relevant premenstrual symptoms and the associated impairment, there is a need for effective treatments. Initial evidence suggests cognitive-behavioural therapy (CBT) as an effective treatment for premenstrual dysphoric disorder (PMDD). The aim of the current randomized clinical trial was to evaluate an Internet-based CBT (iCBT) to reduce the burden of PMDD. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In all, 174 women with PMDD were recruited via newspaper articles, flyers, and social media. They were randomized to a treatment group (TG; &lt;i&gt;n&lt;/i&gt; = 86) or waitlist control group (CG;&lt;i&gt; n&lt;/i&gt; = 88). Women of the TG received an 8-week therapist-guided iCBT. Data were assessed before and after treatment/waiting, and 6 months after intervention with prospective symptom diaries and questionnaires in the premenstrual phase. Treatment effects and moderators were analysed using hierarchical linear modelling. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Significant time × group interaction effects on functional impairment and psychological impairment, impact on everyday life, symptom intensity, and symptom disability in favour of the TG indicated the efficacy of the treatment. Follow-up assessments demonstrated treatment effects to be stable until 6 months after treatment. Additionally, significant interactions with moderator variables were found. In the TG, higher levels of active coping and lower levels of support-seeking coping were associated with stronger improvement in interference in everyday life and symptom intensity. In addition, lower levels of perceived stress were associated with stronger improvement in functional impairment. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; The iCBT was highly effective in reducing the burden of PMDD. It appears to be particularly important to address coping styles and stress management in the treatment.
Splenic rupture in cytomegalovirus infection
Authors: Rachel Farnell, Wenchee Siow, Barbara J. Bain
Journal: American Journal of Hematology (2019)

His full blood count 10 days after surgery showed Hb 92 g/L, WBC 11.4 × 109/L, lymphocyte count 8.1 × 109/L, and platelet count 1068 × 109/L, and a blood film was made. This showed a significant thrombocytosis with platelet anisocytosis. Howell-Jolly bodies were also seen. However, in addition, there were atypical lymphocytes, which were large and irregular in shape with reduced condensation of chromatin and voluminous basophilic cytoplasm, sometimes containing vacuoles or azurophilic granules (Images). No blood film had been made on presentation since the blood count was normal and there was no instrument flag suggesting atypical lymphocytes. Viral serology was positive for cytomegalovirus (CMV) immunoglobulin M antibody and IgG antibody, indicating the patient had current CMV infection. CMV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) was positive and a viral load of 10 600 copies/mL was detected. The patient was treated with a 5-day course of aciclovir 400 mg five times a day. Spontaneous (atraumatic) splenic rupture is rare and most commonly caused by an underlying hematological malignancy or infection. Rarer causes include: hematological disorders causing an increased bleeding tendency such as hemophilia or autoimmune thrombocytopenia; splenomegaly associated with hemolytic anemia; inflammatory causes such as rheumatoid arthritis, polyarteritis nodosa; primary amyloidosis; iatrogenic causes including use of anticoagulants or granulocyte-colony stimulating factor (including cases in healthy stem cell donors); and primary splenic disorders such as splenic cyst, malignancy, or infarction. Infectious mononucleosis is a well-recognized cause but there have also been previous reports of cases due to primary CMV infection.1-15 In one patient, there was not only spontaneous splenic rupture but also very severe virus-related thrombocytopenia underlying the life-threatening hemorrhage.15 Occasional patients have been managed conservatively4, 10 but most have required emergency splenectomy. The authors have no conflict of interest to report.
Notch signaling in bone marrow–derived FSP-1 cells initiates neointima formation in arteriovenous fistulas
Authors: Ming Liang, Qunying Guo, Fengzhang Huang, Guofeng Han, Ke Song, Jinlong Luo, Hunter Cheng, Hongzhen Hu, Eric K. Peden, Changyi Chen, William E. Mitch, Jie Du, Xiaodong Fu, Luan Truong, Jizhong Cheng
Journal: Kidney International (2019)
Reply to Patel and Althouse: Robust Methods Are Needed to Evaluate the Pharmacologic Treatment of Obstructive Sleep Apnea
Authors: Luigi Taranto-Montemurro, Scott A. Sands, Ali Azarbarzin, Andrew Wellman
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

known phenomenon of regression to the mean (3).Because the AHI is known to vary from night to night (4), restricting an analysis to subjects with the highest AHI on one night of placebo treatment results in a subgroup whose AHI would likely be lower if the subjects were simply treated with placebo for a second night.If the analysis is restricted to a subgroup of patients whose AHI on placebo is an overestimate of their true mean AHI, the effect of atomoxetine-oxybutynin in lowering the AHI compared with placebo will also be overestimated.Regression to the mean can explain why those with the highest AHI on placebo showed not only the greatest difference (atomoxetine-oxybutynin 2 placebo) in AHI but also the greatest differences in variables that are correlated with the AHI, such as arousal index, sleep efficiency, and sleep quality.An alternative approach that would provide an unbiased estimate of the true effect of atomoxetine-oxybutynin would be to stratify results on the AHI determined before enrollment rather than on the AHI observed on placebo.The inclusion criteria for this study reported on clinicaltrials.govinclude an AHI of .15events/h, so presumably the authors have an AHI assessment before randomization.Surprisingly, this AHI is not reported in the article and is not used for stratification purposes.This would enable a more valid assessment of whether the response to pharmacologic therapy is greater in patients with more severe OSA.Patients and clinicians eagerly await a pharmacologic treatment for OSA that will be better tolerated than currently available therapies.Despite the hunger for a magic cure, it is important to preserve methodological rigor to ensure that treatments are actually as effective as we say they are.
CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models
Authors: Marion Chapellier, Jun Chen, Carl Sandén, Milena Mazan, Eliza Majewska, Katarzyna Wiklik, Michal Combik, Magdalena Masiejczyk, Elzbieta Fiedor, Marta Obacz, Anna Polak, Arkadiusz Bialas, Paulina Chesy, Ewelina Gabor-Worwa, Przemyslaw Juszczynski, Krzysztof Brzózka, Tomasz Rzymski, Thoas Fioretos, Johan Flygare, Marcus Jaras
Journal: Blood (2018)
GW28-e0705 C-Reactive Protein Causes ERK1/2 Activation and Aggravates Myocardial Ischemia Reperfusion Injury in Primary Culture of Cardiomyocytes
Authors: Weina Pei, Fan Liu, Haijuan Hu, Bing Xiao, Wei Cui
Journal: Journal of the American College of Cardiology (2017)
m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia
Authors: Ly P Vu, Brian F Pickering, Yuanming Cheng, Zaccara Sara, Diu Nguyen, Gerard Minuesa, Timothy Chou, Arthur Chow, Matthew MacKay, Christopher Famulare, Minal Patel, Francine Garret-Bakelman, Ari Melnick, Martin Carroll, Christopher Mason, Samie R. Jaffrey, Michael G. Kharas
Journal: Blood (2017)
Firearm Policies That Work
Authors: April M. Zeoli, Daniel W. Webster
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IL-13 Expression Characterizes Effusions Associated with Primary Effusion Lymphoma but Not Other Disorders Caused By Kaposi Sarcoma Herpesvirus (KSHV)
Authors: Ramya Ramaswami, Kathryn Lurain, Vickie Marshall, Nazzarena Labo, Anaida Widell, Matthew Lindsley, Mark N. Polizzotto, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan
Journal: Blood (2018)
Opioid Use Disorder and Incarceration — Hope for Ensuring the Continuity of Treatment
Authors: Ingrid A Binswanger
Journal: New England Journal of Medicine (2019)

Interview with Dr. Ingrid Binswanger on gaps in treatment for opioid use disorder for people who are incarcerated. (10:16)Download A complex web of legal, policy, and structural barriers has led to persistent gaps in access to treatment for opioid use disorder in jail facilities in the United States and prevented the delivery of coordinated care.
JAMA Network Open—The Year in Review, 2018
Authors: Frederick P. Rivara, Stephan D. Fihn
Journal: JAMA Network Open (2019)

research on clinical care, innovation in health care, health policy, and global health across all health disciplines and countries for clinicians, investigators, and policy makers."We believe that the journal is clearly well on its way to fulfilling this mission.We are grateful that JAMA Network Open has been embraced by the international community who choose to submit to the journal and who read our content each week.We thank the authors who have entrusted us to consider their work.As shown in the Table, 2-5 we have received 1596 research manuscripts in the first year and published 249, for an acceptance rate of 26%.We have also published 100 Invited Commentaries and Editorials that help to put these new research findings into context for the reader, whether they be clinicians, investigators, policy makers, or the general public.We are delighted that 43% of our submissions are from countries outside the United States, reflecting our commitment and mission to being an international journal.We are committed to making this process as smooth and expeditious as possible for authors, as reflected in the time in which decisions are made and